sNDA

FDA Accepts sNDA for NALIRIFOX as First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma

Source: Ipsen Pharma The FDA has accepted a supplemental new drug application (sNDA) for the combination of liposomal irinotecan, 5-fluorouracil, ...